Treatment of Racehorse Superficial Digital Flexor Tendonitis: A Comparison of Stem Cell Treatments to Controlled Exercise Rehabilitation in 213 Cases 

A racehorse on a grass track. Racehorses with superficial digital flexor tendon (SDFT) injuries can benefit from stem cells.
Mesenchymal stem cell treatment is associated with an increased likelihood of returning to racing for Thoroughbreds with SDFT injuries compared to a controlled exercise rehabilitation program alone. RainStar/E+ via Getty Images

Overstrain of the superficial digital flexor tendon (SDFT) is a common Thoroughbred racehorse limb injury requiring treatment. Using clinical treatment records with race records, the aim of this retrospective cohort study was to determine whether treatment of SDFT lesions in flat Thoroughbred racehorses with autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) or allogenic adipose-derived mesenchymal stem cells (A-MSCs) is associated with improved likelihood of returning to racing, when compared to racehorses managed with a controlled exercise rehabilitation program alone.

A total of 213 Thoroughbred racehorses with superficial digital flexor tendon injuries were identified. All were prescribed the same 12-month controlled exercise rehabilitation program. Sixty-six also received intralesional BM-MSC, and 17 received A-MSC treatment. Follow-up was a minimum of 2 years after return to full race training. Multivariable logistic regression models were used to investigate associations between the treatments and the likelihood of returning to racing and completing five or more (C5+) races post-injury.

Compared to controlled exercise rehabilitation program alone, BM-MSC treatment was associated with increased odds of returning to racing (OR 3.19; 95% CI 1.55–6.81) and C5+ races post-injury (OR 2.64; 95% CI 1.32–5.33). Older age and increasing lesion length were associated with a reduced likelihood of returning to racing. Male sex and increased number of pre-injury starts were associated with increased odds of returning to racing. There was no observed increased likelihood of return to racing or C5+ races associated with treatment with A-MSCs compared to controlled exercise rehabilitation program alone.

Bottom Line 

Intralesional BM-MSC treatment was associated with an increased likelihood of returning to racing and C5+ races post-injury compared to controlled exercise rehabilitation program alone. Intralesional A-MSC showed no significant benefit.

https://beva.onlinelibrary.wiley.com/doi/10.1111/evj.13922

categories
tags
Trending Articles
Tierärztin untersucht Sehnenschaden beim Pferd
Disease Du Jour: Diagnosing and Managing Equine Soft Tissue Injuries
[Aggregator] Downloaded image for imported item #18383
Vesicular Stomatitis Outbreak Update: 2 New Affected Premises Confirmed in Arizona
Researchers use a rasp line to measure growth
Field Study Links Balanced Diet With Omneity® to Improved Hoof Growth in Friesians
Horse Twitch
Researchers Assess Horses’ Responses to Lip Twitching
Newsletter
Get the best from EquiManagement delivered straight to your inbox once a week! Topics include horse care, disease alerts, and vet practitioner updates.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Name*
Country*

Additional Offers

Untitled
EquiManagement
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.